Eyepoint study results for vision treatment disappoint, but company still sees promise

EyePoint drug fails pivotal trial, company loses nearly $1 billion in market value

Boston-area biotechnology company EyePoint's main drug candidate failed to hit the central goal of its pivotal LUGANO trial for vision treatment, causing shares to plummet and wiping out nearly a billion dollars in market value.